Skip to main content
Premium Trial:

Request an Annual Quote

Brazilian Bioinformatics Institute Taps Convey's Hybrid-Core System for Genomics Research


Convey Computer said this week that the Brazilian Center for Excellence in Bioinformatics, CEBio, has deployed a Convey HC-1ex hybrid-core computer to handle its genomic data analysis needs.

CEBio is part of the Oswald Cruz Foundation, a scientific institution for research and development in biomedical sciences located in Rio de Janeiro.

According to Guilherme Oliveira, CEBio's coordinator and president of the Brazilian Association for Bioinformatics and Computational Biology, Convey's system will enable CEBio's researchers to speed up their bioinformatics applications; reduce power consumption and costs; and solve computationally intensive problems such as large genome assemblies.

Researchers will use the system to assemble genomes from species like bovine and swine, as well as to handle transcriptomic data analysis, he said.

Prior to purchasing Convey's system, CEBio relied on a 256-node cluster that took too long to complete genomic assemblies, he said.

Convey's hybrid-core architecture pairs Intel x86 microprocessors with a coprocessor comprised of field-programmable gate arrays. It also includes bioinformatics algorithms for DNA sequence mapping and alignment (BI 10/14/2011) and (BI 11/20/2009); and the Convey GraphConstructor which is used to construct and manipulate de Bruijn graphs commonly used in short-read genome assembly applications (BI 5/20/2011).

Additional performance and workflow optimizations include a k-mer counting tool for identifying optimal k-mer length and coverage cutoffs for de novo assembly.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.